OTX-2002, a first-in-class, programmable mRNA therapeutic that regulates MYC gene expression by epigenomic modulation, is currently being evaluated for use in patients with HCC and other advanced solid tumors in the MYCHELANGELO I study (NCT05497453) (148, 149). Here, MYC is linked to hepatocellular carcinoma.